USA's GAO says drugs not enough to stem or avoid bird flu pandemic

28 January 2008

The US Government Accountability Office has issued its assessment of the federal administration's efforts to prepare for a possible influenza pandemic (Marketletters passim). The report, titled Influenza Pandemic: Efforts Under Way to Address Constraints on Using Antivirals and Vaccines to Forestall a Pandemic, accepts the view of the World Health Organization that a new strain of the H5N1 flu virus is a potential public health threat. However, the GAO also notes that uncertain effectiveness and limited availability will hamper efforts to cope with an outbreak of the disease.

The congressional watchdog noted that, "due to the time required to identify the virus and develop and manufacture a pandemic vaccine - 20 to 23 weeks according to [the Department of Health and Human Services] HHS - such vaccines are likely to play little or no role in efforts to forestall a pandemic in its initial stages." The GAO also warned that efforts to improve the speed of vaccine development would take several years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight